Navigating the Frontiers of Regenerative Medicine.

Regenerative medicine company Celularity, which uses cells derived from the human placenta, is weathering the biotech investment downturn by supporting its therapeutics business with income from its range of biomaterials products. The company recently announced that it was expecting purchase orders for its regenerative biomaterials in the order of up to $80m in 2023 from the Middle East alone. Celularity's focus on generating revenue does not mean the company has put its therapeutic work on the back burner, with longevity a key area of its focus, with programs in autoimmune and degenerative diseases.